CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Close on Oct 19, 2026
- Market cap
- $14.41B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 27, 2026 | Aug 5, 2026 | Before market open | $1.00B | $-0.03 | $3.02 |
| Q1 FY2026 Ended Mar 28, 2026 | May 7, 2026 | Before market open | $995.80M | $-0.30 | – |
| Q4 FY2025 Ended Dec 27, 2025 | Jan 13, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 27, 2025 | Nov 5, 2025 | Before market open | $1.00B | $1.10 | $2.43 |
| Q2 FY2025 Ended Jun 28, 2025 | Aug 6, 2025 | Before market open | $1.03B | $1.06 | $3.12 |
| Q1 FY2025 Ended Mar 29, 2025 | May 7, 2025 | Before market open | $984.20M | $0.50 | $2.34 |
| Q4 FY2024 Ended Dec 28, 2024 | Feb 19, 2025 | Before market open | $1.00B | $-4.22 | $2.66 |
| Q3 FY2024 Ended Sep 28, 2024 | Nov 6, 2024 | Before market open | $1.01B | $1.33 | $2.59 |
| Q2 FY2024 Ended Jun 29, 2024 | Aug 7, 2024 | Before market open | $1.03B | $1.74 | $2.80 |
| Q1 FY2024 Ended Mar 30, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 30, 2023 | Feb 14, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Non-GAAP EPS estimatenon-GAAP | 2026 | $11.15 to $11.45 | Raised |
| GAAP EPS estimateGAAP | 2026 | $3.05 to $3.35 | Lowered |
| Revenue growth/(decrease), organicnon-GAAP | 2026 | 0% to 1% growth | Raised |
| Revenue growth/(decrease), reportedGAAP | 2026 | -3.5% to -2.5% growth | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Charles River Laboratories International filed with the SEC
Charles River Laboratories Announces Second-Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
of $(0.30), and Non-GAAP Earnings per Share of $2.06 –
Results of operations · EX-99.1 to Form 8-K
CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER
Results of operations · EX-99.1 to Form 8-K
and Non-GAAP Earnings per Share of $2.43 –
Results of operations · EX-99.1 to Form 8-K
Michael G. Knell, Corporate Senior Vice President & Chief Accounting Officer,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
and Non-GAAP Earnings per Share of $3.12 –
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces Governance
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
and Non-GAAP Earnings per Share of $2.34 –
Results of operations · EX-99.1 to Form 8-K
CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER
Results of operations · EX-99.1 to Form 8-K
and Non-GAAP Earnings per Share of $2.59 –
Results of operations · EX-99.1 to Form 8-K
and Non-GAAP Earnings per Share of $2.80 –
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces Third-Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces Second-Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces First-Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces Third-Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces Second-Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces First-Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results
Results of operations · EX-99.1 to Form 8-K
EVERY STEP OF THE WAY © 2022 Charles River Laboratories International, Inc. JP Morgan 40th Annual Healthcare Conference James C. Foster Chairman, President & Chief Executive Officer Charles River Laboratories January 11, 2022
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Charles River Laboratories Announces Third-Quarter 2021 Results
Results of operations · EX-99.1 to Form 8-K